Literature DB >> 1782374

Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis.

J R Fiatarone1, S A Coverdale, R G Batey, G C Farrell.   

Abstract

Non-alcoholic steatohepatitis resembles alcoholic liver disease in hepatic morphology but appears to have a different natural history. We sought to assess the nature of non-alcoholic steatohepatitis by a prospective study of its clinical progression and the relationship of biochemical abnormalities to changes in serum lipids among 15 patients with this disorder. In addition, antipyrine clearance (Cl-AP), which reflects hepatic microsomal oxidative capacity, was measured serially. Although initial liver histology included micronodular cirrhosis in five cases and bridging fibrosis in another three, only one patient developed a hepatic complication during 1-10 years (median: 3.7) of follow up. This confirms the relatively benign nature of non-alcoholic steatohepatitis. Moreover, Cl-AP, which was below the normal range in 13 patients, did not change significantly during 10-40 months of follow up. However, compared with other chronic liver diseases, the reduced Cl-AP was disproportionately low relative to the uniformly normal serum albumin concentration and other indices of hepatic metabolic function. This is consistent with selective impairment of endoplasmic reticular drug oxidizing enzymes. Hyperlipidaemia was present in 11 patients. In three of these, diet-induced correction of serum triglyceride elevation was associated with reduction of hepatocellular damage as indicated by serum enzyme levels. A hypothesis that unites these and earlier findings is that release of cytokines may occur in non-alcoholic steatohepatitis and produce accumulation of free fatty acids in the liver, leading to focal necro-inflammatory lesions and the destruction or down-regulation of cytochrome P450.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1782374     DOI: 10.1111/j.1440-1746.1991.tb00915.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

Review 1.  Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?

Authors:  François Cauchy; David Fuks; Alban Zarzavadjian Le Bian; Jacques Belghiti; Renato Costi
Journal:  World J Hepatol       Date:  2014-05-27

2.  Metabolic disorders, non-alcoholic fatty liver disease and major liver resection: an underestimated perioperative risk.

Authors:  Alban Zarzavadjian Le Bian; Renato Costi; Vassilis Constantinides; Claude Smadja
Journal:  J Gastrointest Surg       Date:  2012-10-09       Impact factor: 3.452

Review 3.  Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism.

Authors:  Jie Gao; Wen Xie
Journal:  Drug Metab Dispos       Date:  2010-08-24       Impact factor: 3.922

Review 4.  Post-translational modification of pregnane x receptor.

Authors:  Jeff L Staudinger; Chenshu Xu; Arunima Biswas; Sridhar Mani
Journal:  Pharmacol Res       Date:  2011-03-21       Impact factor: 7.658

5.  Differentially regulated protein kinase A (PKA) activity in adipose tissue and liver is associated with resistance to diet-induced obesity and glucose intolerance in mice that lack PKA regulatory subunit type IIα.

Authors:  Edra London; Maria Nesterova; Ninet Sinaii; Eva Szarek; Tatyana Chanturiya; Spyridon A Mastroyannis; Oksana Gavrilova; Constantine A Stratakis
Journal:  Endocrinology       Date:  2014-06-10       Impact factor: 4.736

6.  Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Authors:  Qiumei Zhou; Yulong Wang; Jiajia Wang; Yating Liu; Dehui Qi; Wei Yao; Hui Jiang; Tingting Li; Kaiquan Huang; Wancun Zhang; Xingxing Huo
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

7.  Urine metabolic profile changes of CCl4-liver fibrosis in rats and intervention effects of Yi Guan Jian Decoction using metabonomic approach.

Authors:  Xiaojun Gou; Qing Tao; Qin Feng; Jinghua Peng; Yu Zhao; Jianye Dai; Wenyu Wang; Yongyu Zhang; Yiyang Hu; Ping Liu
Journal:  BMC Complement Altern Med       Date:  2013-06-03       Impact factor: 3.659

Review 8.  A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma.

Authors:  François Cauchy; Jacques Belghiti
Journal:  J Hepatocell Carcinoma       Date:  2015-02-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.